## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

- (Previously Presented) (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at one or more positions selected from the group consisting of 9.1-9.2 (±0.1), 16.0-16.1 (±0.1), 18.0-18.2 (±0.1), and 18.3-18.4 (±0.1) degrees.
- 2. (Original) The substantially crystalline form as claimed in claim 1 in the form of needle-shaped crystals.
- 3. (Original) The substantially crystalline form as claimed in claim 1 in the form of lath-shaped crystals.
- 4. (Original) The substantially crystalline form as claimed in claim 1 in the form of a mixture of needle-shaped and lath-shaped crystals.
- 5. (Previously Presented) The substantially crystalline form as claimed in claim 1 wherein the melting point is greater than 160°C.
- 6. (Previously Presented) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at two or more positions selected from the group consisting of 9.1-9.2 (±0.1), 16.0-16.1 (±0.1), 18.0-18.2 (±0.1), and 18.3-18.4 (±0.1) degrees.

- 7. (Previously Presented) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at three or more positions selected from the group consisting of 9.1-9.2 (±0.1), 16.0-16.1 (±0.1), 18.0-18.2 (±0.1), and 18.3-18.4 (±0.1) degrees.
- 8. (Previously Presented) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at all four positions selected from the group consisting of 9.1-9.2 (±0.1), 16.0-16.1 (±0.1), 18.0-18.2 (±0.1), and 18.3-18.4 (±0.1) degrees.
- 9. (Canceled)
- 10. (Canceled).
- 11. (Canceled).
- 12. (Canceled).
- 13. (Previously Presented) A method for the preparation of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form which method comprises crystallisation of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide from an organic solution, optionally in the presence of water.
- 14. (Original) A method as claimed in claim 13 wherein the organic solution selected from: an aromatic hydrocarbon, a cycloalkane, an ester, an alcohol or a ketone, or a mixture thereof.
- 15. (Cancelled).
- 16. (Cancelled).

- 17. (Cancelled).
- 18. (Cancelled).
- 19. (New). The substantially crystalline form as claimed in claim 1, wherein substantially crystalline form is meant substantially free of an amorphous form or solvated form of (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide.